From startups to legacy brands, you're making your mark. We're here to help.
Key Links
Prepare for future growth with customized loan services, succession planning and capital for business equipment.
Key Links
Institutional Investing
Serving the world's largest corporate clients and institutional investors, we support the entire investment cycle with market-leading research, analytics, execution and investor services.
Key Links
Providing investment banking solutions, including mergers and acquisitions, capital raising and risk management, for a broad range of corporations, institutions and governments.
Key Links
A uniquely elevated private banking experience shaped around you.
Whether you want to invest on your own or work with an advisor to design a personalized investment strategy, we have opportunities for every investor.
Explore a variety of insights.
Key Links
Insights by Topic
Explore a variety of insights organized by different topics.
Key Links
Insights by Type
Explore a variety of insights organized by different types of content and media.
Key Links
We aim to be the most respected financial services firm in the world, serving corporations and individuals in more than 100 countries.
Key Links
Despite a more discerning financing environment, 2023 saw bright spots with substantial opportunities for clinical stage biotechs.
Early stage licensing deals continued to take the lion’s share of deal flow, however, biopharma companies with lead programs in Phase II trials saw higher than average deal sizes.
While Q4 licensing and partnership activity saw deal count continue to taper, total capital raised was the highest in history. The average Seed and Series A deal size reached levels not seen since 2021 and 2019. Remarkably, total M&A deal value was higher in Q4, even with fewer deals.
J.P. Morgan’s biopharma licensing and venture report explores the developments in therapeutics and offers insight into the industry trends that shaped 2023. The report, powered by DealForma, highlights:
Read the full report to better understand these dealmaking trends.
Kathryn McDonough
Head of Life Sciences, Innovation Economy, Commercial Banking, J.P. Morgan
Skip Kelly
Head of Healthcare VC Coverage, Commercial Banking, J.P. Morgan
Outlook
April 2024 jobs report: 175,000 jobs added, lower than forecast
May 06, 2024
The U.S. economy added 175,000 jobs in April, signaling a rebalancing labor market.
Outlook
Midnight musings: 3 risks keeping us up at night
May 03, 2024
Risks abound – from high rates and frothy valuations to election uncertainty. Here’s how investors can stay vigilant.
Outlook
May 2024 Fed meeting: Rates hold steady
May 03, 2024
The Federal Reserve held rates steady and described an uncertain path toward rate cuts in 2024. Read more about the implications of the Fed’s latest decision.
Outlook
Biopharma and medtech venture investments trend up in Q1
Apr 29, 2024
Our Biopharma and Medtech Licensing and Venture Reports explore upfront cash, mergers, acquisitions and other trends seen since January.
Outlook
Nerves tested. Are stocks disconnected from reality?
Apr 26, 2024
Growth is solid, not stagnant. Inflation is sticky, not high. Here’s why stocks are so resilient.
Outlook
Eye on the market: Cicadian rhythms
Apr 24, 2024
The latest Eye on the Market relates the co-emergence of two batches of cicadas to the rare event of markets pricing in a U.S. disinflationary boom earlier this year.
Outlook
Geopolitical unrest: Assessing market implications
Apr 19, 2024
Some investors worry Middle East tensions could impact inflation, making it tricky for central banks. Top Market Takeaways digs into what we’re watching and what it could mean for investors.
Outlook
Does it matter if the Fed cuts?
Apr 12, 2024
If growth is solid and inflation doesn’t reaccelerate, we continue to see opportunity for investors.
You're now leaving J.P. Morgan
J.P. Morgan’s website and/or mobile terms, privacy and security policies don’t apply to the site or app you're about to visit. Please review its terms, privacy and security policies to see how they apply to you. J.P. Morgan isn’t responsible for (and doesn’t provide) any products, services or content at this third-party site or app, except for products and services that explicitly carry the J.P. Morgan name.